Differential Neutralization Profiles of 17DD Vaccinated Population to 17D-204 and 17DD Vaccine Strains

Autor(es)

Terzian, Ana C. B. ; Azar, Sasha R. ; Estofolete, Cassia F. ; Nogueira, Mauricio L. ; Vasilakis, Nikos

• Tipo de documento: Artigo Científico
• Fonte: VACCINES; v. 12, n. 12, p. 8-pg., 2024-12-01.

Resumo

Background/Objectives: Yellow fever virus (YFV) (Flaviviridae, Orthoflavivirus) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil). Vaccines produced in the US, France, Senegal, China, and Russia represent 17D-204-derived strains, whereas the Brazilian 17DD has a unique passage/attenuation history from 17D-204-derived strains. Their functional differences in the neutralization profiles are not known. Methods: The Plaque Reduction Neutralization Test (PRNT) was used to determine the neutralization profiles of sera from 209 patients that were previously vaccinated with the 17DD strain against both 17D-204 and 17DD. Results: Sera exhibited significantly more efficient neutralization of 17DD (mean reciprocal PRNT50 183, PRNT80 86, median reciprocal PRNT50 80, and PRNT80 40) compared to 17D-204 (mean reciprocal PRNT50 91, PRNT80 33, median reciprocal PRNT50 40, and PRNT80 10). Conclusions: Our data indicate antigenic differences between 17D and 17DD vaccines. (AU)

• Processo FAPESP: 22/03645-1 - Estudo da interação vírus-vetor e dos mecanismos envolvidos na modulação da dinâmica de transmissão viral
• Beneficiário: Maurício Lacerda Nogueira
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 22/09229-0 - Influência da exposição prévia ao Vírus Zika na infecção aguda por Dengue: aspectos epidemiológicos, clínicos, imunológicos e virológicos
• Beneficiário: Cássia Fernanda Estofolete
• Modalidade de apoio: Auxílio à Pesquisa - Regular